8-K filing — Alector, Inc. (ALEC)
Filed: 2026-10-16 AccNo: 0001193125-26-424204 Size: 423 KB Item 1.01: Entry into a Material Definitive Agreement Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Stocks · News reference
Alector Reports Third Quarter 2026 Financial Results
Alector, Inc. reported its third-quarter 2026 financial results, highlighting a net income of $124.6 million driven by the recognition of deferred revenue following the termination of its agreement with GSK.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Alector Prices $75.03M Common Stock Offering Of 36.6M Shares At $2.05/Share
Fastenal To Rally More Than 15%? Here Are 10 Top Analyst Forecasts For Thursday
Analysts raised targets for TSM, MRNA, ALEC and WMT; cut AZZ, ARRY and ALGN targets, upgrading ARRY/WMT and downgrading ALGN.
HC Wainwright & Co. Maintains Buy on Alector, Raises Price Target to $8
HC Wainwright & Co. analyst Andrew S. Fein maintains Alector (NASDAQ:ALEC) with a Buy and raises the price target from $5 to $8.
Morgan Stanley Maintains Underweight on Alector, Raises Price Target to $3
Morgan Stanley analyst Sean Laaman maintains Alector (NASDAQ:ALEC) with a Underweight and raises the price target from $2 to $3.
Alector shares are trading higher after the company announced an exclusive global licensing agreement granting Genentech worldwide rights to develop and commercialize its AL050 program.